



SDI Review Form 1.6

Journal Name:	International Journal of Research and Reports in Hematology
Manuscript Number:	Ms_IJR2H_47045
Title of the Manuscript:	EVALUATION OF EFFECT OF IMATINIB ON BONE MARROW FIBROSIS IN CHRONIC MYELOID LEUKEMIA PATIENTS
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>A multiparametric analysis is recommended. Supplemental data should be included for full data evaluation and understanding of the statistical analysis.</p> <p>Results should be better explained, especially statistical analysis. A data table showing BM fibrosis at presentation and after one year would be interesting for individual assessment of patients</p>	<ul style="list-style-type: none"> As regarding multiparametric analysis, we currently have another study (in progress) with a larger number of patients and also to compare other TKIs in use. We updated the results section (highlighted)
Minor REVISION comments	Title should be changed for including Lon-term evaluation of imatinib effect on bone marrow fibrosis	We changed the title to the title you suggested (highlighted).
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	The study was approved by the Ethical Committee of Faculty of Medicine, Assiut University (IRB no: IRB00008718). Informed consents were taken from the patients before enrollment in this study.